Variant · Expression
IGF1R Overexpression
CI-VAR-00003213Explore in graph →CIViC 3259
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26706833
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| IGF1R Overexpression | Exemestane + MetforminCombination | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID10138A randomized phase III trial of hormone sensitive (ER or PR positive) early stage breast cancer (Dutch TEAM cohort, n=2,446) examined the addition of metformin to exemestane for 155 patients. IGF1R IH… (full text at CIViC) PMID 26706833 · Engels et al., 2016 · Open in CIViC | civic |
| Salivary Gland Adenoid Cystic Carcinoma1 | ||||||||
| IGF1R Overexpression | Crizotinib + Gefitinib + LinsitinibCombination | Predictive | D | Supports Sensitivity Response | 3 | submitted | ||
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.